LYEL - Lyell Immunopharma, Inc.
IEX Last Trade
0.667
-0.015 -2.174%
Share volume: 45,537
Last Updated: Thu 26 Dec 2024 08:30:10 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$0.68
-0.01
-2.13%
Summary score
12%
Profitability
0%
Dept financing
3%
Liquidity
75%
Performance
11%
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
Long-term ratios 2020 - 2024
The data are presented for the financials results of the quarters of the last 4 years.
Return on equity
-7.13%
Return on assets
-6.32%
Return on sales
-574254.65%
Return on invested capital
-25.65%
Total debt ratio
13.43%
Debt ratio change over timeo
-2.04%
Current Ratio
16.24%
Quick Ratio
16.24%
Cash Position Ratio
15.96%
Short-term ratios 2023 - 2024
The data are presented for the financials results of the quarters of the last year.
Return on equity
-8.53%
Return on assets
-7.83%
Return on sales
-711237.41%
Return on invested capital
-35.66%
Total debt ratio
12.46%
Debt ratio change over timeo
-1.45%
Current Ratio
16.74%
Quick Ratio
16.74%
Cash Position Ratio
16.46%
Last quarter ratios 2024
The data are presented for the financials results of the last quarter.
Return on equity
-10.06%
Return on assets
-8.01%
Return on sales
-1888833.33%
Return on invested capital
-47.51%
Total debt ratio
13.12%
Debt ratio change over time
-1.4%
Current Ratio
16.51%
Quick Ratio
16.51%
Cash Position Ratio
16.27%
Performance ratios (change over 4 years) 2020 - 2024
The data are presented for the change financials results of the quarter of the last 4 years.
Return on equity
-45.74%
Return on assets
-54.46%
Return on sales
8348334.76%
Return on invested capital
75.56%
Total debt ratio
-203.68%
Debt ratio change over time
-2.04%
Current Ratio
-104.02%
Quick Ratio
-104.02%
Cash Position Ratio
-102.2%
Compare in sector
The following table compares the individual analyzes for the other top 3 stocks within the same industry.
| Long-term ratios | LYEL | ABBV | AMGN | REGN |
|---|---|---|---|---|
| Return on equity | -7.13% | 13.79% | 34.47% | 7.43% |
| Return on assets | -6.32% | 2.76% | 3.15% | 5.62% |
| Return on sales | -574254.65% | 28.74% | 32.53% | 40.48% |
| Return on invested capital | -25.65% | 2.36% | 5.39% | 19.77% |
| Profitability | 0% | 43% | 66% | 80% |
| Total debt ratio | 13.43% | 90.46% | 90.54% | 26.74% |
| Debt ratio change over time | -2.04% | 308.97% | -6.99% | 1.18% |
| Dept financing | 4% | 50% | 25% | 7% |
| Current Ratio | 16.74% | 0.91% | 2.18% | 5.4% |
| Quick Ratio | 16.74% | 0.8% | 1.79% | 4.64% |
| Cash Position Ratio | 16.46% | 0.36% | 1.28% | 2.93% |
| Liquididy | 75% | 3% | 7% | 16% |
| Short-term ratios | LYEL | ABBV | AMGN | REGN |
|---|---|---|---|---|
| Return on equity | -8.53% | 13.77% | 13.25% | 3.8% |
| Return on assets | -7.83% | 2.43% | 1.89% | 3.09% |
| Return on sales | -711237.41% | 24.64% | 23.72% | 30.49% |
| Return on invested capital | -35.66% | 2.14% | 3.39% | 9.18% |
| Profitability | 0% | 71% | 68% | 82% |
| Total debt ratio | 12.46% | 92.14% | 93.05% | 21.79% |
| Debt ratio change over time | -1.45% | 46.38% | -72.08% | 1.51% |
| Dept financing | 3% | 50% | 25% | 7% |
| Current Ratio | 16.74% | 0.91% | 2.18% | 5.4% |
| Quick Ratio | 16.74% | 0.8% | 1.79% | 4.64% |
| Cash Position Ratio | 16.46% | 0.36% | 1.28% | 2.93% |
| Liquididy | 75% | 3% | 8% | 19% |